NCPA Staff

James H. Amos, Jr., President & CEOJim Amos was named President and CEO of the National  Center for Policy Analysis in February, in 2016. Mr. Amos is the former CEO …

Ron Lyon

IT Director As IT Director, Ron Lyon oversees all of the activities of the NCPA's IT department. These activities include Web site design and development, email administration for both individual …

Joe Barnett

Sr. Director of Policy Research As director of policy research, Joe Barnett is responsible for the NCPA’s publishing program, working with academic authors, independent experts and the NCPA policy staff …

Richard W. Walker

Chief Operating Officer Richard W. Walker is responsible for the day-to-day operations of all departments and functions at the NCPA.   Prior to coming to the NCPA, Richard served as the …

Jeanette N. Goodman

Chief Development Officer Jeanette N. Goodman is Chief Development Officer at the National Center for Policy Analysis (NCPA). She is responsible for raising the NCPA's budget each year. Under her …

NCPA Board of Directors

Steve IvySteve Ivy is Chairman of the Board of Directors for the National Center for Policy Analysis and CEO of Heritage Auctions. Heritage has offices in Dallas, New York and …

Robert J. Wright

President – TWG, Inc. Mr. Wright is the Chairman and CEO of Medical Cities, Inc., the Crow-Wright Company, and Managing Partner of Medical City Dallas, Ltd. He is President of …

Raymond E. Wooldridge

Private Investor Raymond E. Wooldridge is a private investor who was formerly vice chairman and chairman of the Executive Committee of Southwest Securities Group, Inc., a publicly owned holding company …

Jere W. Thompson

Compensation Committee Chairman – NCPA; President – The Williamsburg Corporation Jere W. Thompson, NCPA Board member and former Chairman of the Board, is the president of The Williamsburg Corporation. He …

James C. Thompson, Jr.

Chairman of the Board – Thompson Petroleum Corporation Independent Oil & Gas Producer, Ranching, Banking, Investments. Managing General Partner, J. Cleo Thompson & James Thompson, Jr., A Partnership, engaged in …

Henry J. "Bud" Smith

Chairman – Bud Smith Organization Henry J. Smith is Chairman Emeritus for Clark/Bardes, Inc. Dallas, Texas. Clark/Bardes is an executive compensation firm with offices in most major cities throughout the …

Fred Meyer

Governance Committee Chairman – NCPA;  President,CEO,& COB – Aladdin Industries, LLC. Mr. Meyer has served as chairman of the board of Aladdin Industries, LLC (formerly Aladdin Industries, Inc.) since 1985. …

John Victor Lattimore, Jr.

President and Chairman of the Board – Lattimore Properties, Inc. John Victor Lattimore is president and chairman of the board of Lattimore Properties, Inc (LPI). Lattimore Properties is the General …

Don A. Buchholz

Chairman Emeritus – SWS Group, Inc Don A. Buchholz is Chairman Emeritus of SWS Group, Inc., a publicly-owned holding company with subsidiaries engaged in providing securities clearing, securities brokerage, investment banking …

W. Mike Baggett

Chairman and CEO, Winstead Sechrest & Minick P.C. W. Mike Baggett has been Chairman and CEO of the law firm of Winstead Sechrest & Minick P.C. since 1992. The firm …

John C. Goodman, PhD.

John C. Goodman is president and CEO of the National Center for Policy Analysis and author of the new book, Priceless: Curing the Healthcare Crisis. He is widely known as the ‘Father of Health Savings Accounts’ and Modern Healthcare named him as one of four people who have most influenced the modern health care system.

Pete du Pont

Pete du Pont Pete du Pont is a regular columnist on www.opinionjournal.com, the editorial page website of The Wall Street Journal. Entitled, Outside the Box, du Pont’s columns discuss current …

Medicare: Negotiated Drug Prices May Not Lower Costs

Rep. Nancy Pelosi has promised that within its first 100 hours the Democrat-controlled House will repeal the ban preventing Medicare from negotiating directly with pharmaceutical companies. She must expect this legislation to bring down drug prices dramatically. However, it is not obvious that allowing the government to negotiate with pharmaceutical companies will lead to lower prices than those achieved by private drug plans. There are several good reasons why not.